KTX 049
Alternative Names: KTX-049Latest Information Update: 21 Feb 2024
At a glance
- Originator Kymera Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-mdm2 degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Merkel cell carcinoma
Most Recent Events
- 11 Oct 2023 Preclinical trials in Merkel cell carcinoma in USA (unspecified route), prior to October 2023
- 11 Oct 2023 Pharmacodynamics data from a preclinical trial in Merkel cell carcinoma presented at the International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 21 Oct 2018 Kymera Therapeutics files for patent protection for protein degraders worldwide